Director / PDMR Shareholding

Diaceutics PLC

23 May 2024

 

Director / PDMR Shareholding - NED Purchase of Shares

Belfast and London, 23 May 2024 - Diaceutics PLC (AIM: DXRX) ("Diaceutics" or the "Company"), a leading technology and solutions provider to the pharma and biotech industry announces that on 22 May 2024, Graham Paterson, a Non-Executive Director of Diaceutics, purchased 39,934 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.2889 per Ordinary Share. As a result of the purchase, Graham Paterson's shareholding in Diaceutics is 73,498 Ordinary Shares representing approximately 0.09% of the Company's issued share capital.

Enquiries: 

Diaceutics PLC
Ryan Keeling, Chief Executive Officer   Nick Roberts, Chief Financial Officer	Tel: [phone] [e-mail]
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Strategic Communications	Tel: [phone]
Caroline Forde	[e-mail]

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Graham Paterson
2	Reason for notification
a.	Position/Status	Non-Executive Director
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)		Share purchase:
			Price(s)	Volume(s)
			£1.2889	39,934
d.	Date of the transaction	22 May 2024
e.	Place of the transaction	AIM Market of the London Stock Exchange

 

END